Modeling phenotypes of malignant gliomas

Oltea Sampetrean | Hideyuki Saya

Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan

Correspondence
Oltea Sampetrean, Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. Email: oltea@a6.keio.jp

Funding information
This work has been partially supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT, Kakenhi grant No. 22249055) to H.S and O.S.

Abstract
Malignant gliomas are primary tumors of the central nervous system characterized by diffuse infiltration into the brain and a high recurrence rate. Advances in comprehensive genomic studies have provided unprecedented insight into the genetic and molecular heterogeneity of these tumors and refined our understanding of their evolution from low to high grade. However, similar levels of phenotypic characterization are indispensable to understanding the complexity of malignant gliomas.

Experimental glioma models have also achieved great progress in recent years. Advances in transgenic technologies and cell culture have allowed the establishment of mouse models that mirror the human disease with increasing fidelity and which support single-cell resolution for phenotypic analyses. Here we review the major types of preclinical glioma models, with an emphasis on how recent developments in experimental modeling have shed new light on two fundamental aspects of glioma phenotype, their cell of origin and their invasive potential.

KEYWORDS
experimental model, genetically engineered mouse model, glioma cell of origin, glioma invasion, malignant glioma

1 | INTRODUCTION

Malignant gliomas are primary tumors that arise in the central nervous system. They are characterized clinically by progression from low to higher malignancy grades and by a response to a limited range of therapies. Biologically, their malignancy is the result in part of a high level of heterogeneity and of diffuse infiltration into normal brain tissue. Our understanding of the genetic makeup and molecular biology of malignant gliomas has seen great advances over the last few years. Progress in genomics, epigenomics, and data-mining is revealing previously unknown characteristics of these tumors. The Cancer Genome Atlas study and several subsequent studies have thus characterized their patterns of somatic mutations, genome-wide DNA copy number alterations, and DNA methylation status.1,2 As a result of these findings, the World Health Organization classification of gliomas was revised to add a layer of molecular information to the classical pathology-based system.3 Furthermore, biodata portals now offer access to large international databases of such findings that allows researchers to verify the expression of their molecule of interest, analyze prognosis, and integrate clinical, genomics, and transcriptomics data.4

However, high-grade gliomas are heterogeneous, not only at the genetic level but at the cellular level. An equally detailed phenotypic characterization of these tumors and the linking of genomic landscapes to appropriate phenotypes will also be indispensable for the translation of preclinical knowledge into therapeutic strategies. Pertaining largely to cellular biology, questions regarding the cell of origin for gliomas and their diffuse infiltration into the brain parenchyma can be investigated only in animal models.

For more than 50 years, animal models have increased our understanding of human disease and have been instrumental in mechanism discovery and in validation of treatment targets and therapies.5 Recent advances in the development of such models—in particular, in the establishment of genetically engineered models—have...
also opened the door to single-cell resolution for phenotypic analysis.

We here briefly review current experimental models of malignant gliomas and outline the latest findings regarding two defining aspects of glioma biology: the cell of origin and tumor cell invasion.

2 | ANIMAL MODELS OF MALIGNANT GLIOMAS: TYPES AND CHARACTERISTICS

Gliomas are categorized histologically as such on the basis of glial morphology, and graded based on the presence of nuclear atypia (grade II and higher), mitotic activity (grade III and higher), or necrosis or microvascular proliferation (grade IV) on pathological examination. Grade IV gliomas, also known as glioblastomas, are among the solid tumors with the highest recurrence rates, the worst prognosis, and the fewest therapeutic options. These tumors spread insidiously into normal brain tissue and to distant regions beyond the reach of surgery or radiotherapy. They hijack and destabilize the existing microvascular network, and they secrete soluble factors that change the surrounding stroma, lead to self-renewal of malignant cells, and induce aberrant angiogenesis.6,7

High grade malignant gliomas, especially glioblastomas, are also known for their large number of genetic aberrations. These include mutations in tumor suppressor genes—such as TP53, CDKN2A, RB1, PTEN, and NF1—and enhancements in key signaling pathways such as MAPK and PI3K (phosphatidylinositol 3-kinase)–Akt.1,2

Ideally, experimental models should reproduce all of these histopathologic characteristics and should closely resemble human gliomas in their genetic and epigenetic profiles. Depending on the focus of the investigation, several additional requirements may arise. To ensure an undisrupted microenvironment with an intact blood-brain barrier (BBB) and immune response, studies on prevention and early detection of glioma would ideally be performed with spontaneous models, or at least with models that avoid physical manipulation of the brain. At the same time, the models should show a penetrance sufficient to allow evaluation of statistical significance. Studies focused on treatment should be performed with models that replicate the heterogeneity of human tumors, given that oversimplification with the use of a single type of cell or genetic aberration might yield results that are misleading with regard to drug efficacy and lead to failure of clinical studies.8 Furthermore, the requirements regarding the microenvironment also apply to treatment studies. Tumor formation must be highly reproducible and tumor penetrance and latency should also be adequate for assessment of treatment effects.

Even if a single preclinical model of malignant glioma could fulfill all of these conditions necessary to mimic human disease, researchers would still have to adjust for species and strain differences, making validation in several models necessary. To date, available models can be classified into spontaneous, chemically induced, genetically engineered, and transplantation categories, with each type of model being best suited to investigate specific aspects of disease evolution (Figure 1, Table 1).

2.1 | Spontaneous gliomas

Extensive research on brain scrapie with the use of 23 inbred mouse strains led to the discovery that astrocytomas occur with the highest frequency among spontaneous neuroectodermal tumors and that they recapitulate human glioma characteristics such as spread along white matter tracts.9 However, their development was found to be
| Model                      | Advantages                                                                 | Disadvantages                                                   | Recent advances | Examples |
|----------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------|----------------|----------|
| Spontaneous                | Intact blood-brain barrier (BBB), microenvironment (ME)/ tumor microenvironment (TME) | Low prevalence                                                  |                | 9-11     |
|                            | Intact immune response                                                     | Low reproducibility                                             |                |          |
|                            | All stages of tumor development                                            | Strain dependency                                               |                |          |
| Chemically induced         | Intact immune system                                                       | Variable predictability                                         |                | 12,13    |
|                            | No external manipulation of brain                                           | Variable reproducibility                                       |                |          |
|                            | All stages of tumor development                                            | Tumors in other organs                                         |                |          |
| Genetically engineered     | Constitutive                                                               | Presence of genetic alteration during development not desirable for adult tumors |                | 14,38    |
|                            | Mimic gradual tumor development                                            | Do not always recapitulate genomic heterogeneity and instability |                |          |
| Conditional                | ±Intact BBB, ME/TME                                                        | Complex genetic engineering                                     | Use in combination with allografts                            | 17-22    |
|                            | Temporal and spatial control of transgene expression                       | Do not always recapitulate genomic heterogeneity and instability | Use of genomic editing to improve efficiency and simultaneous induction of multiple alterations |          |
|                            | Mimic gradual tumor development                                            | Labor-intensive and space-consuming                             |                |          |
| Transplantation             | Xenografts                                                                 | Relatively short latency                                        | Use of serum-free, sphere culture to maintain heterogeneous phenotype | 27-30    |
|                            | Predictable engraftment and proliferation rates                            | Diminished immune response                                      | Establishment of "humanized" mouse models                      |          |
|                            | High reproducibility                                                       | Disrupted BBB and ME due to physical manipulation of the brain  | Grafting patient-derived tissue that includes stroma           |          |
|                            | Tumors have human expression profiles and heterogeneity                    | ±Limited reproducibility of invasion patterns                   |                |          |
|                            | ±Predict drug response for tumors of patient origin                        |                                                                  |                |          |
| Allografts                  | Intact immune response                                                     | Disrupted BBB and ME due to physical manipulation of the brain  |                | 35,36    |
|                            | Short latency                                                              | Do not always recapitulate genomic heterogeneity of human tumors |                |          |
|                            | High reproducibility                                                       |                                                                   |                |          |
|                            | Reproducibility of invasion patterns                                       |                                                                   |                |          |
|                            | Evaluation of tumor-host interaction                                       |                                                                   |                |          |

TABLE 1 Overview of glioma model types and of their advantages and disadvantages
limited to a small number of strains, mainly VM and BRVR, and their incidence was still only ~1%.9,10 On the other hand, dogs show a glioma incidence closer to that in humans and the tumors present with similar mutations such as those in TP53 and EGFR,11 but ethical considerations and low availability of suitable animal care facilities preclude large-scale studies of these animals.

2.2 | Chemically induced models

The administration of carcinogens to initiate intracranial neoplasms represents one of the earliest types of induced glioma model. Transplacental administration of N-methyl-N-nitrosourea or N-ethyl-N-nitrosourea to pregnant rats has mutagenic effects on the intrauterine embryos, resulting in a high incidence of brain tumors.12 Gliomas established in this manner contain cells that manifest deletions or mutations in p16\(^{ink4a}\) or TP53 or aberrant expression of epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor, or Ras,13 similar to their human counterparts. Their microenvironment and the BBB have not been disrupted by external manipulation, and the immune system remains intact. However, the predictability and reproducibility of tumor formation by chemical induction are variable. Allografts of clones established from such models and propagated in vitro, such as C6 and 9L gliomas, now constitute their most extensive application.13

2.3 | Genetically engineered mouse models

The genetic alterations characteristic of human gliomas have been mimicked in genetically engineered mouse models (GEMMs) in a variety of ways depending on the desired outcome. Introduction of an event of interest into embryonic cells or zygotes can result in the engineered change being expressed at the germline level, whereas direct editing of somatic cells has been applied to establish somatic GEMMs. Expression of a transgene can be permanent (constitutive), or it can be induced by several methods (conditional).

2.3.1 | Constitutive engineered models

Murine gliomas can be established by forced gain or loss of one or multiple genes of interest. An example in this category is provided by mice engineered to harbor mutations in the tumor suppressor genes Nf1 and TP53 on the same chromosome (NPcis mice), which develop a range of astrocytomas, from low grade to glioblastoma.14 In constitutive models, the presence of the genetic alteration (or alterations) during development can have undesired effects, and these models do therefore not necessarily provide a faithful recapitulation of adult gliomas. However, their relative ease of use after establishment is a major advantage. Constitutive engineered mice such as the NPcis model have shown that a combination of alterations in two tumor suppressor genes can be sufficient to elicit glioma formation.

2.3.2 | Conditional engineered models

Generation of mice that harbor a gene of interest flanked by loxP sequences and then crossing them with mice that express Cre recombinase under the control of a cell type–specific gene promoter allows tissue- or cell type–specific transgene expression. In the mouse brain, glial fibrillary acidic protein (GFAP) is expressed in subventricular zone neural stem cells (NSCs) and mature astrocytes, whereas nestin is expressed in NSCs as well as neural and endothelial progenitors.15,16 Crossing of p53\(^{-/-}\);Nf1\(^{flox}\) mice with mice that express Cre recombinase under the control of the human GFAP gene promoter introduces the mutations into developing NSCs and mature astrocytes that express GFAP.17 Offspring with the targeted genotype form gliomas with 100% penetrance and a survival time of 20-45 weeks.17

Expression of transgenes can also be controlled at the temporal level. Using mice that express Cre recombinase under the control of the nestin gene promoter linked to a tamoxifen-responsive sequence (Nestin-Cre-ER\(^{T2}\) mice) thus allows targeting of the adult NSC population by administration of tamoxifen beginning at 4 weeks of age. This approach, used to achieve conditional inactivation of tumor suppressors p53, Nf1 and Pten, also generates grade III or IV gliomas with a high penetrance.18

The major advantages of conditional transgenic mice are the high degree of control over the desired genetic outcome and the lack of any direct physical manipulation of the brain before or during tumor formation. Brain homeostasis, the BBB, and the tumor microenvironment therefore remain intact, rendering these models suitable for a large variety of studies, including those focusing on tumor initiation and treatment evaluation.

However, the study of multiple mouse lines is expensive, labor-intensive, and space-consuming. In modeling of brain tumors, these limitations can be circumvented by injection-based gene transfer, albeit with the cost of a degree of interference with the microenvironment. For instance, injection of a lentivirus encoding Cre recombinase into the brain of loxP-based transgenic mice can result in the formation of gliomas. Stereotactic intracranial injection of self-deleting lentiviral vector that confers Cre expression under the control of the CMV promoter into 8- to 16-week-old mice harboring combinations of floxed alleles of p16\(^{ink4a}\)/p19\(^{Arf}\), oncogenic Kras\(^{V12}\), and TP53 results in the formation of high-grade gliomas that are lethal within as short a period as 2 weeks.19 Another versatile approach based on gene transfer to somatic cells is the replication-competent ALV splice acceptor (RCAS)/Tva system, in which mice are engineered to express the ALV-A retrovirus receptor tv-a under the control of the GFAP or nestin gene promoter (Gtv-a and Ntv-a, respectively), resulting in astrocyte- or neural stem-progenitor cell-specific expression of the receptor.20,21 The targeted cells are rendered susceptible to infection with avian leukosis virus (ALV)-derived RCAS vectors containing expression cassettes for oncogenes of interest such as Pdgfb or Egrf. Infection is achieved by injection of chicken fibroblasts producing the RCAS vectors into the desired region of the brain.20,21 This model has been successfully adopted in
a large variety of studies, ranging from testing the oncogenic potential of various genetic aberrations to elucidation of the molecular characteristics of glioma stem cells.20-22

Finally, genome editing technologies have recently started to provide new opportunities in cancer modeling. The clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system can be applied to mouse zygotes to generate animals that harbor the targeted genetic modifications. A detailed protocol for generating mouse models with this system has been described.23 This versatile technology can produce knockout, mutant, targeted alleles in the mouse and might therefore become a preferred choice for cancer modeling in the future.24 In utero electroporation of the ventricular zone in the cerebrum of wild-type mice at embryonic day 13.5 to achieve the simultaneous delivery of three plasmids encoding Cas9 as well as guide RNAs targeting Nf1, Tp53, and Pten has resulted in the establishment of tumors with glioblastoma-like pathology. With a penetrance of 100% and initiation of tumor formation apparent between 6 and 14 weeks after electroporation, this technique has been proposed as a fast and convenient system for the generation of new animal models.25

2.4 | Transplantation models

Stereotactic injection of glioma cells into the forebrain of experimental animals is one of the most reproducible and widely adopted glioma models.

2.4.1 | Xenograft models

Most xenograft models are based on implantation of human glioma-derived cell lines or primary cultures of patient-derived cells or multicellular aggregates into the brain of immunocompromised mice. Cell lines that originate from patient gliomas and have been cultured as a monolayer in the presence of serum have been used extensively for this purpose for many years. They have predictable proliferation and engraftment rates26 and form tumors that recapitulate expansive growth and manifest a degree of angiogenesis, necrosis, and invasion.27 However, the formed tumors are more homogeneous than the parental tumors or human gliomas in general, and they usually show relatively limited single-cell invasiveness and invasion along white matter tracts.26,27 The lack of syngeneic tumor-host interaction—including interaction of the tumor with stromal and immune cells—and the consequent absence of remodeling of the tumor microenvironment may account in part for the differences with the characteristics of the parental tumor.

Culture of glioma cell lines in serum-containing medium has emerged as another factor that limits maintenance of the original tumor phenotype.28 In contrast, culture of glioma cells in medium conditioned to sustain stem cells—usually by supplementation with epidermal growth factor, basic fibroblast growth factor, as well as a cocktail of antioxidants and insulin—has proved instrumental not only for enrichment of a cell population with stem cell characteristics but also for maintenance of the original properties of primary cultures, including infiltrative potential of individual cells and endothelial cell proliferation.28,29 Such systems have also been used for the culture of primary oligodendroglioma cells30 and for derivation of NSCs from human embryonic stem cells for subsequent transformation and establishment of difficult-to-model pediatric gliomas.31

Implantation of spheroids from biopsied tumor tissue was one of the earliest approaches introduced for reconstitution of a portion of the original tumor microenvironment. Minced tumor tissue is cultured until multicellular aggregates form. These outgrowths maintain the structure and composition of the biopsied tissue, including endothelial cells, macrophages, and extracellular matrix from the original tumor.32 In recent years, this approach has been further refined and single-cell suspensions prepared from freshly excised glioma specimens have also been successfully transplanted into rodent brains as orthotopic patient-derived xenografts.

In summary, xenografts are the tool of choice for the modeling and investigation of tumors with human expression profiles, and advances in cell culture and harvesting techniques have expanded the types of analyses that can be performed with this model. Of note, advances in whole-transcriptome analysis, such as the development of RNA sequencing (RNA-seq), now allow improved accuracy in the discrimination of human and mouse transcripts, and such approaches can be used to further dissect the interactions between tumor cells and nonmalignant host cells, as shown for patient-derived xenografts for multiple solid tumors and for cell line–based models of metastatic brain tumors.33,34

2.4.2 | Allograft models

Syngeneic transplantation models allow interrogation of both tumor initiation and response to treatment in the context of an intact anti-tumor immune response. The earliest allografts were generated by intracranial injection of mouse cell lines originating from chemically induced tumors. The GL261 mouse cell line was established by the administration of 3-methylcholanthrene to C57BL/6 mice. It harbors Tp53 and Kras mutations, yields tumors with a high penetrance, and has been successfully applied to studies of immune and gene therapies.35

Cell lines derived from GEMMs have also been adopted in transplantation experiments. Although this application diminishes the initial advantage of these models for tumor initiation studies, the short and predictable tumor formation time in a syngeneic environment makes the derived cell lines useful for therapeutic studies. Similar results can be achieved by the introduction of specific genetic alterations into isolated mouse NSCs and intracranial implantation of the transformed cells.36 We have shown that forced expression of oncogenic H-RasV12 in neural stem-progenitor cells isolated from mice with deletion of p16^{Ink4a}/p19^{Arf} gives rise to glioma stemlike cells that form glioblastoma-like tumors. These tumors have a high morphologic heterogeneity and manifest single-cell invasion, pseudopalisading, and pronounced vascular proliferation.36
3 | ANIMAL MODELS AT WORK: CURRENT RESEARCH TOPICS

Diversification and fine-tuning of animal models of malignant glioma have helped answer questions unapproachable by other investigative methods. Some of the newly found answers to these questions are summarized below.

3.1 | Cell of origin

Given the histological and molecular heterogeneity of malignant gliomas, it is possible that, by the time of treatment, the cell of origin is no longer present or does not constitute the most therapy-resistant clone in the tumor. However, the ability to unequivocally identify the cells that initiate gliomas not only will deepen our understanding of this malignancy but also might lead to the discovery of molecular markers useful for early diagnosis.

There has been much speculation regarding the differentiation status of the cell of origin, and many animal studies have addressed this issue. The central nervous system of adult mice comprises several types of cell populations that can develop or have developed glial characteristics, including NSCs, astrocytic and oligodendrocyte precursor cells (OPCs), and differentiated astrocytes. Forced expression studies have provided insight into the possible scenarios and combinations of genetic aberrations that can underlie initiation of a mouse glioma.

With the use of mice deficient for p16\(^{ink}\), p19\(^{Arf}\) or both, Bachoo and colleagues showed that loss of both p16\(^{ink}\) and p19\(^{Arf}\) is sufficient for dedifferentiation of astrocytes in serum-free culture and also renders these cells susceptible to transformation by a constitutively active mutant of EGFR (VIIEGFR). In contrast, loss of p16\(^{ink}\), p19\(^{Arf}\), or Tp53 alone was not sufficient for astrocyte dedifferentiation.

Uhrbom et al. found that expression of K-Ras, but not of Akt, in Gtv-a-positive astrocytes deficient in p16\(^{ink}\) and p19\(^{Arf}\) can lead to tumor initiation. Of note, in both studies, the same genetic lesions were also able to induce the formation of tumors from NSCs. Other combinations of genetic alterations have been found to induce the initiation of murine gliomas from neural stem-progenitor cells but not from astrocytes. Together, these studies show that, at least in experimental settings and under the right conditions, both astrocytes and NSCs can be primed to initiate murine gliomas.

Advances in refinement of cell lineage markers and GEMM-based lineage tracing have proved instrumental for validation of these possible scenarios. For instance, placing a target gene under control of the nestin gene promoter-enhancer and intron-2 regulatory element restricts its expression to NSCs. Together with the application of tamoxifen-inducible recombination, such a system can lead to highly controllable glioma induction. Mosaic analysis with double markers (MADM) relies on the Cre-loxP system to achieve conditional knockout of target genes during mitotic recombination and, at the same time, to complete the sequence needed to express a green fluorescent reporter in the mutant cells and a red fluorescent reporter in sibling wild-type cells. This model has advanced phenotypic analysis and lineage tracing to the level of single-cell resolution, and it was applied by Liu and colleagues to show that loss of Tp53 and Nf1 leads to expansion of OPCs and, ultimately, to glioma formation, without a similar effect on NSCs, astrocytes, or neurons.

Among the many gliomagenic possibilities uncovered by forced expression models, lineage-tracing GEMMs thus allow the selection of combinations of oncogenic events and recipient cells that can coevolve with the microenvironment. However, even such models are not completely free of bias, given that they are also based on predetermined genetic lesions. Refinement of lineage markers, identification of molecular markers for the earliest malignant cells, and the application of these molecular markers to validation studies and to the development of diagnostic markers are the main goals for this area of research.

3.2 | Invasion

Seminal pathology studies showed that gliomas undergo diffuse infiltration into the surrounding brain, manifesting several invasion patterns: perineuronal, perivascular, subpial, and along myelinated fibers. Animal models have been indispensable for validation of in vitro findings concerning molecular regulators of cell motility, chemotactic factors, and tumor cell-matrix interactions. They have
also provided insight into the relation between invasive phenotypes and molecular and epigenetic regulators.45,46 Furthermore, as with regard to the cell of origin, the combination of new models, visualization at single-cell resolution, and the switch to growth factor-based culture has led to the discovery of novel invasion characteristics.

For glioma cell lines grown in serum-containing medium and then transplanted into the mouse brain, the major pattern of invasion is the collective infiltration of tumor cells from the edge of the mass into the adjacent brain. Cloning of invasive cell subpopulations and microdissection to allow extraction of proteins from invasive cells in paraffin-embedded tissue specimens have been the principal approaches adopted to the establishment and analysis of cells with infiltrative potential.47 With the advent of stem cell culture, a wide array of cell lines, genetically engineered stemlike cells,36 as well as glioma cells from fresh surgical specimens29 has been shown to possess a high infiltrative potential, as demonstrated for murine glioma cells in Figure 2A (right panel). While it remains to be determined to what extent this ability is due to the change in culture conditions (replacement of serum with growth factors) or to an intrinsic characteristic of stemlike cells, the ability to visualize single-cell invasion in real time has helped answer the following questions:

3.2.1 When does invasion start?

A decrease in oxygen and nutrient availability at the tumor core causes glioma cells to search for more permissive environments. This scenario suggests that invasion occurs relatively late in the tumor formation process, certainly later than mass formation. Using our model of H-RasV12–expressing glioma-initiating cells, we have shown that this is not necessarily the case: On implantation into the forebrain of wild-type mice, these cells infiltrate the parenchyma before they form a tumor at the injection site.36 Given that this is an implantation model, the results speak only to the ability of murine glioma-initiating cells to begin invasion at such an early stage. Exploitation of GEMMs with an intact microenvironment should reveal exactly when invasion starts during tumorigenesis, whether transformed NSCs that initiate tumors migrate away from their subventricular zone niches, and how astrocytes behave if they become malignant. Characterization of the trajectory of these cells during tumor initiation might reveal hidden invasion pathways that tumor cells can reuse. For instance, it might explain certain invasion patterns, such as the typical infiltration of tumor cells along the ventricles, infiltration that can lead to a “butterfly” appearance.29

![Figure 2](image-url)

**FIGURE 2** Invasion characteristics of a murine glioma model based on Ink4a/Arf−/− neural stem-progenitor cells transduced with H-RasV12. A, Hematoxylin-eosin staining of organotypic brain slices derived from mice 10 days after implantation of 1000 tumor cells and cultured in the presence of serum (left) or growth factors (right). Scale bars, 100 μm. B, Sequential images of a cultured brain slice from the model mice showing a single tumor cell before, during, and after division (arrowheads). Times represent hours:minutes. T, tumor. Scale bar, 30 μm.
3.2.2 | Are proliferation and invasion mutually exclusive?

Isolation of invasive subpopulations from glioma cell lines has shown that these cells have a lower proliferation rate than their noninvasive counterparts. The accumulation of similar experimental data led to the hypothesis of an inverse correlation between cell motility and proliferation. Summarized by the expression “go or grow,” this dichotomy appears to be partially true. However, real-time imaging of glioma-initiating cells has shown that the period during which proliferating cells cease migration is much shorter than initially thought. Using explants of brain slices harboring H-RasV12-expressing tumors, we found that tumor cells indeed slow their migration before dividing, but that they can restart migration within hours after mitosis (Figure 2B). Although consistent with results from other transplantation models, in which proliferating cells were shown to cease migration for as little as an hour, this finding will need to be further investigated with GEMMs and intravitreal imaging. At present, it suggests that invading cells might be more responsive to therapy than previously considered, given that they are not all quiescent. However, it also suggests that anti-invasion therapies need to be continuous and initiated as early as possible.

3.2.3 | How do tumor cells communicate?

Long-term multiphoton imaging of intracranial xenografts formed by patient-derived glioblastoma cell lines maintained in serum-free, stem cell–favorable culture conditions has revealed a previously unknown type of connection between tumor cells known as “tumor microtubes.” Tumor microtubes are ultra-long, actin-rich, membrane protrusions that infiltrate the brain at the invasion front and serve as tracks for the travel of nuclei after mitosis. They can achieve a length of up to 500 μm and have been detected even in the hemisphere contralateral to the tumor in the case of astrocytomas. Furthermore, tumor microtubes are long-lived, having been found to persist for months, and they can serve not only as a physical scaffold for invasion but also as a conduit for the propagation of intercellular calcium waves, thus allowing instrumental in the fine-tuning of therapy, and the models will be further advanced at the same time by feedback from such trials.

DISCLOSURE

H.S. has received research grants from Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Nihon Noyaku Co. Ltd., Pola Pharma Inc., and AQUA Therapeutics Co. Ltd. The other author has no conflict of interest.

ORCID

Oltea Sampetrean
http://orcid.org/0000-0001-5783-1049

REFERENCES

1. The Cancer Genome Atlas (TCGA) Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-1068.
2. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRα, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
3. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803-820.
4. Colaprico A, Silva TC, Olsen C, et al. TCGAbiobikins: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71.
5. Rosenthal N, Brown S. The mouse ascending: perspectives for human-disease models. Nat Cell Biol. 2007;9:993-999.
6. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:829-848.
7. Gilbertson RJ, Rich JM. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007;7:733-736.
8. Klinghammer K, Walther W, Hoffmann J. Choosing wisely – Preclinical test models in the era of precision medicine. Cancer Treat Rev. 2017;55:36-45.
9. Fraser H. Brain tumours in mice, with particular reference to astrocytoma. Food Chem Toxicol. 1986;24:105-111.
10. Kiebish MA, Han X, Cheng H, Chuang JH, Seyfried TN. Brain mitochondrial lipid abnormalities in mice susceptible to spontaneous gliomas. Lipids. 2008;43:951-959.
11. Stoica G, Kim HT, Hall DG, Coates JR. Morphology, immunohistochemistry, and genetic alterations in dog astrocytomas. Vet Pathol. 2004;41:10-19.
12. Bilzer T, Reifenberger G, Wechsler W. Chemical induction of brain tumors in rats by nitrosoureas: molecular biology and neuropathology. Neurotoxicol Teratol. 1989;11:551-556.
13. Barth RF, Kaur B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol. 2009;94:299-312.
14. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. NF1; Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet. 2000;26:109-113.
15. Alcantara Llaguno SR, Parada LF. Cell of origin of glioma: biological and clinical implications. Br J Cancer. 2016;115:1445-1450.
16. Lépinoux-Chambaud C, Eyer J. Review on intermediate filaments of the nervous system and their pathological alterations. Histochem Cell Biol. 2013;140:13-22.
17. Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell. 2005;8:119-130.
18. Alcantara Llaguno SR, Chen J, Kwon CH, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell. 2009;15:45-56.

19. De Vries NA, Bruggeman SW, Hulsman D, et al. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies. Clin Cancer Res. 2010;16:3431-3441.

20. Holland EC, Varmus HE. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci USA. 1998;95:1218-1223.

21. Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 1998;12:3675-3685.

22. Pietras A, Katz AM, Ekstrom EJ, et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell. 2014;14:357-369.

23. Qin W, Kutny PM, Maser RS, et al. Generating mouse models using CRISPR-Cas9-mediated genome editing. Curr Protoc Mouse Biol. 2016;6:39-66.

24. Guernet A, Grumolato L. CRISPR/Cas9 editing of the genome for cancer modeling. Methods. 2017;121:122-130.

25. Zuckermann M, Hofvestad T, Knobbe-Thomsen CB, et al. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat Commun. 2015;6:7391.

26. Claes A, Schuuring J, Boots-Sprenger S, et al. Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol. 2008;18:423-433.

27. Candolfi M, Curtin JF, Nichols WS, et al. Intracranial glioblastoma models in preclinical neuro-ophthalmology: neuropathological characterization and tumor progression. J Neurooncol. 2007;85:133-148.

28. Lee J, Kotliarov S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the tumor phenotype and genotype in glioblastoma stem cell lines. Cancer Cell. 2006;9:391-403.

29. Wakimoto H, Mohapatra G, Kanai R, et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012;14:132-144.

30. Kelly JJ, Blough MD, Stechishin OD, et al. Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro Oncol. 2010;12:745-755.

31. Funato K, Major T, Lewis PW, Allis CD, Tabar V. Use of embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science. 2014;346:1529-1533.

32. Bjerkvig R, Tønnesen A, Laerum OD, Backlund EO. Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg. 1990;72:463-475.

33. Bradford JR, Wappett M, Beran G, et al. Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers. Oncotarget. 2016;7:20773-20787.

34. Sato R, Nakano T, Hosonaga M, et al. RNA sequencing analysis reveals interactions between breast cancer or melanoma cells and the tissue microenvironment during brain metastasis. Biomed Res Int. 2017;2017:8032910.

35. Szatmári T, Lumniczky K, Désaknai S, et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 2006;97:546-553.

36. Sampetrean O, Saga I, Nakanishi M, et al. Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. Neoplasia. 2011;13:784-789.

37. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343:189-193.

38. Bachoo RM, Maher EA, Ligon KL, et al. Epidermal growth factor receptor and Ink4a-Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 2002;1:269-277.

39. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC. Ink4a-Arf loss cooperates with KRAs activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res. 2002;62:5551-5558.

40. Jacques TS, Swales A, Brzozowski MJ, et al. Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumor phenotypes. EMBO J. 2010;29:222-235.

41. Holland EC, Celestino J, Dai C, Schafer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 2000;25:55-57.

42. Zong H, Espinosa JS, Su HH, Muzumdar MD, Luo L. Mosaic analysis with double markers in mice. Cell. 2005;121:479-492.

43. Liu C, Sage JC, Miller MR, et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell. 2011;146:209-211.

44. Scherer HJ. The forms of growth in gliomas and their practical significance. Brain. 1940;63:1-35.

45. Keonen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108:3749-3754.

46. Hu B, Wang Q, Wang YA, et al. Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth. Cell. 2016;167:1281-1295.

47. Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol. 2014;16:1575-1584.

48. McDonough W, Tran N, Giese A, Norman SA, Berens ME. Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase. J Neuroonathol Exp Neurol. 1998;57:449-455.

49. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21:1624-1636.

50. Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P. Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia. 2006;53:799-808.

51. Osswald M, Jung E, Sahm F, et al. Brain tumour cells interconnect to a functional and resistant network. Nature. 2015;528:93-98.

52. Weil S, Osswald M, Soleciki G, et al. Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas. Neuro Oncol. 2017;19:1316-1326.

53. Kioi M, Vogel H, Schultz G, Hoffman RM, Brown JM. Inhibition of vasculosgenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120:694-705.

54. Niclou SP, Danzeisen C, Elkedal HP, et al. A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. FASEB J. 2008;22:3120-3128.

55. Lucca LE, Hafler DA. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immuno Rev. 2017;276:9-25.

56. Zitvogel L, Pitt JM, Daillère R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer. 2016;16:759-773.

57. Pitter KL, Galban CJ, Galban S, et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS ONE. 2011;6:e14545.

58. Malaney P, Nicosa SV, Davé V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 2014;344:1-12.

How to cite this article: Sampetrean O, Saya H. Modeling phenotypes of malignant gliomas. Cancer Sci. 2018;109:6-14.
https://doi.org/10.1111/cas.13351